Eye movement

The Ohana, Hawaii's Luxury Rehab, Announces New Support Programs for Addiction Patients and Their Families

Retrieved on: 
星期四, 十二月 21, 2023
Substance abuse, Garden, Family, Rehabilitation, Trauma, Education, Freedom, Mental health, Eye movement, Growth, Pacific Ocean, Patient, EMDR, Cognitive behavioral therapy, Rejuvenation, Environment, Nursing

Both services align with the luxury drug rehab's commitment to empowering its clients with the latest in addiction treatments and recovery support techniques.

Key Points: 
  • Both services align with the luxury drug rehab's commitment to empowering its clients with the latest in addiction treatments and recovery support techniques.
  • The Ohana is a luxury drug and alcohol rehab in beautiful Hawaii.
  • Additionally, The Ohana has launched a program to provide education and therapy to the families of its clients.
  • The facility's staff understands that while the recovery journey centers on the patient, their loved ones require vital support as well.

PESI gifts $1.25 million to UC College of Medicine

Retrieved on: 
星期四, 二月 9, 2023
Science, Veteran, Eye movement desensitization and reprocessing, Cognitive processing therapy, Eye movement, PTSD, DSM-IV codes, Chard, Prolonged exposure therapy, Research, CPT, Knowledge, UC, Trauma, EMDR, PESI, Doctor of Philosophy, Psychiatry, Nursing, Meat

EAU CLAIRE, Wis., Feb. 9, 2023 /PRNewswire/ -- A $1.25 million gift from PESI will allow researchers at the UC College of Medicine to explore therapies used for posttraumatic stress disorder (PTSD).

Key Points: 
  • "I'm incredibly grateful to PESI for allowing me to make an important and valuable contribution to the science," Chard said.
  • "People are looking for answers and want to trust that the therapy they are offered will work.
  • This study offers a significant step forward in helping us understand how many viable treatment options there are for people suffering from stress responses."
  • "Our mission is to connect knowledge with the needs of mental health clinicians," said Mike Conner, executive director of PESI.

CES 2023: Somalytics revolutionizes at-home sleep monitoring with launch of first eye-tracking sleep mask

Retrieved on: 
星期四, 十二月 15, 2022
Consumer Technology Association, Memory, University of Washington, Heart, CoMotion, Interview, SDK, Snoring, Transport, AR, Learning, Sleep, Nano, Privacy, CPC, Internet, Fatigue, CES, Human, Eye, Disease, Multimedia, Concussion, Nanotechnology, REM, University, Condon Hall (University of Washington), Health, WRF, Stroke, Eye movement, IOT, Consumer electronics, Instrumentation, Camera

SEATTLE, Dec. 15, 2022 /PRNewswire/ -- CES 2023 Innovation Awards honoree and nanotechnology pioneer Somalytics Inc. announced today it will be unveiling its new SomaSleep sleep mask at CES Unveiled on Jan. 3, 2023, and showcasing it during CES 2023 Jan. 5-8, 2023, in Las Vegas. SomaSleep is a first-of-its-kind sleep mask that uses eye tracking to unmask the wellness challenges preventing better sleep by collecting data never before possible through an in-home device. The revolutionary sleep mask can track eye movements, including rapid eye movements, to help consumers better understand sleep stages, quality and disruptions, which is key to gaining wellness insights and improving sleep.

Key Points: 
  • SomaSleep is a first-of-its-kind sleep mask that uses eye tracking to unmask the wellness challenges preventing better sleep by collecting data never before possible through an in-home device.
  • The revolutionary sleep mask can track eye movements, including rapid eye movements, to help consumers better understand sleep stages, quality and disruptions, which is key to gaining wellness insights and improving sleep.
  • Visit Somalytics during CES 2023 Jan. 5-8: Las Vegas Convention Center Central Hall, booth 18490.
  • "Sleep problems affect the lives of billions of people, and understanding the quality of sleep is at the heart of the solution," said Barbara Barclay , CEO of Somalytics.

Eye Tracking Market is to Reach USD 1383.9 Million by 2028 at a CAGR of 21.1% | Valuates Reports

Retrieved on: 
星期五, 七月 15, 2022
Stroke, Research, Muscular dystrophy, Medical research, Hardware, Driver Monitoring System, Patient, Neurodegeneration, Advertising, ALS, Cerebral palsy, Communication, CAGR, Original equipment manufacturer, Medicine, Spinal cord injury, Adoption, Technology, Attention, EYE, Dementia, Brain, Parkinson's disease, Fatigue, Government budget balance, VR, Alzheimer's disease, AR, Human Behaviour, Autism, Behavior, Brain damage, Growth, SGD, USD, Speech, Eye, Eye movement, Huntington's disease, ACC, Rett syndrome, AAC, Toy, Software

The global Eye Tracking market size is projected to reach USD 1383.9 million by 2028, from USD 350.8 million in 2021, at a CAGR of 21.1% during 2022-2028.

Key Points: 
  • The global Eye Tracking market size is projected to reach USD 1383.9 million by 2028, from USD 350.8 million in 2021, at a CAGR of 21.1% during 2022-2028.
  • Increasing application of eye tracking in Assistive Communication, Human Behavior & Market Research, AR/VR, and vehicles is expected to drive the growth of the eye tracking market.
  • Increasing use of Eye Tracking in Human Behavior & Medical Research is expected to drive the eye tracking market growth.
  • Eye movements nearly always indicate the presence of conditions like brain damage and cognitive impairment.

Eye Tracking Market is to Reach USD 1383.9 Million by 2028 at a CAGR of 21.1% | Valuates Reports

Retrieved on: 
星期五, 七月 15, 2022
Stroke, Research, Muscular dystrophy, Medical research, Hardware, Driver Monitoring System, Patient, Neurodegeneration, Advertising, ALS, Cerebral palsy, Communication, CAGR, Original equipment manufacturer, Medicine, Spinal cord injury, Adoption, Technology, Attention, EYE, Dementia, Brain, Parkinson's disease, Fatigue, Government budget balance, VR, Alzheimer's disease, AR, Human Behaviour, Autism, Behavior, Brain damage, Growth, SGD, USD, Speech, Eye, Eye movement, Huntington's disease, ACC, Rett syndrome, AAC, Toy, Software

The global Eye Tracking market size is projected to reach USD 1383.9 million by 2028, from USD 350.8 million in 2021, at a CAGR of 21.1% during 2022-2028.

Key Points: 
  • The global Eye Tracking market size is projected to reach USD 1383.9 million by 2028, from USD 350.8 million in 2021, at a CAGR of 21.1% during 2022-2028.
  • Increasing application of eye tracking in Assistive Communication, Human Behavior & Market Research, AR/VR, and vehicles is expected to drive the growth of the eye tracking market.
  • Increasing use of Eye Tracking in Human Behavior & Medical Research is expected to drive the eye tracking market growth.
  • Eye movements nearly always indicate the presence of conditions like brain damage and cognitive impairment.

ETNA™ DEVICE FROM THE LEADING DIGITAL HEALTH & AI COMPANY INNODEM NEUROSCIENCES RECEIVES FDA "BREAKTHROUGH" DESIGNATION FOR MULTIPLE SCLEROSIS

Retrieved on: 
星期二, 五月 31, 2022
Google Images, Magnetic resonance imaging, MRI, SPMS, Goto, De novo, Literature, Self-test of intelligence, EMB Consultancy, Sclerosis, Quality of life, Clinical trial, Algorithm, Neurodegeneration, Brain, Alzheimer's disease, EDSS, Multiple sclerosis, DC, Frontotemporal dementia, PPMS, Eye, RRMS, Eye movement, GMB (trade union), IVD, Robotics, MCRA, Elective surgery, McGill University, Partnership, General surgery, Spine, Consultant, Parkinson's disease, Neuroscience, Patient, Neurology, Industry, Urology, Minuteman Library Network, Biomarker, Contract research organization, CRO, Technology, HIV disease progression rates, HIPAA, Intelligence, Diagnosis, Medical device, CEO, Medical imaging

"Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.

Key Points: 
  • "Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.
  • However, this technology was complex to use, expensive, and the data collected did not allow clinicians to benefit from it for their patients.
  • Up until now, with current standard of care in MS, several years are usually required before clinicians confidently establish the presence of disease progression.
  • www.innodemneurosciences.com
    MCRA is the leading privately held independent medical device and biologics Clinical Research Organization (CRO) and advisory firm.

ETNA™ DEVICE FROM THE LEADING DIGITAL HEALTH & AI COMPANY INNODEM NEUROSCIENCES RECEIVES FDA "BREAKTHROUGH" DESIGNATION FOR MULTIPLE SCLEROSIS

Retrieved on: 
星期二, 五月 31, 2022
CEO, Google Images, Consultant, Parkinson's disease, PPMS, Eye, Neuroscience, RRMS, Partnership, Magnetic resonance imaging, Eye movement, Patient, MRI, GMB (trade union), SPMS, Sclerosis, IVD, Quality of life, Neurology, Clinical trial, Robotics, MCRA, Algorithm, Goto, McGill University, Neurodegeneration, Brain, Elective surgery, Industry, Urology, De novo, Literature, Minuteman Library Network, Biomarker, Contract research organization, Alzheimer's disease, Self-test of intelligence, CRO, EDSS, General surgery, Multiple sclerosis, Technology, HIV disease progression rates, HIPAA, Intelligence, Spine, EMB Consultancy, Diagnosis, DC, Medical device, Frontotemporal dementia, Medical imaging

"Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.

Key Points: 
  • "Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.
  • However, this technology was complex to use, expensive, and the data collected did not allow clinicians to benefit from it for their patients.
  • Up until now, with current standard of care in MS, several years are usually required before clinicians confidently establish the presence of disease progression.
  • www.innodemneurosciences.com
    MCRA is the leading privately held independent medical device and biologics Clinical Research Organization (CRO) and advisory firm.

Vestibular First adds enhanced infection control to low-cost vertigo diagnostic tool

Retrieved on: 
星期一, 一月 10, 2022
Balance disorder, Audiology, Eye movement, Patient, Vertigo, Lists of diseases, Occupational therapy, Rehabilitation, Dizziness, COVID-19, Movement, Safety, PT, NCS, Computer, Otorhinolaryngology, Infection, DPT, Multimedia, FDA, Prevalence, Engineering, Software, COVID, Pharmaceutical industry, Medical imaging

BROOMALL, Pa., Jan. 10, 2022 /PRNewswire/ --Vestibular First LLC today announced it has added a new infection control measure to its FDA-cleared, low-cost tool for diagnosing dizziness, imbalance and vertigo, which affects over 10 million American adults.

Key Points: 
  • BROOMALL, Pa., Jan. 10, 2022 /PRNewswire/ --Vestibular First LLC today announced it has added a new infection control measure to its FDA-cleared, low-cost tool for diagnosing dizziness, imbalance and vertigo, which affects over 10 million American adults.
  • Eye movements are key information in putting together the puzzle of why a given patient may have dizziness and balance disorders like vertigo, said Vestibular First Co-Founder Patrick Esmonde.
  • Balance disorders like vertigo and dizziness can interfere with a patient's daily activities and can often be debilitating.
  • Insight Pro's durable silicone cushion can now be easily swapped with a new disposable cushion, which aids in infection control an important consideration during the COVID-19 pandemic.

Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.

Retrieved on: 
星期二, 十月 5, 2021
Clinical trial, Neurodegeneration, Partnership, EDSS, Frontotemporal dementia, MRI, Diagnosis, GMB, Novartis, Solution, Parkinson's disease, MSFC, Eye movement, Alzheimer's disease, Multiple sclerosis functional composite, CEO, MS, Magnetic resonance imaging, Biomarker, EMB Consultancy, HIV disease progression rates, Technology, Gold, GMB (trade union), Neuroscience, Multiple sclerosis, Digital, Pharmaceutical industry, Medical imaging

MONTREAL, Oct. 5, 2021 /PRNewswire/ - Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).

Key Points: 
  • MONTREAL, Oct. 5, 2021 /PRNewswire/ - Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).
  • "The financing from Novartis will fund a carefully designed cross-sectional and longitudinal MS study that will last until 2027.
  • "This partnership is the result of an ongoing collaboration that was architected over the past two years.
  • "At Novartis, we are committed to innovation and becoming the leaders in the health tech space.

Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.

Retrieved on: 
星期二, 十月 5, 2021
Clinical trial, Neurodegeneration, Partnership, EDSS, Frontotemporal dementia, MRI, Diagnosis, GMB, Novartis, Solution, Parkinson's disease, MSFC, Eye movement, Alzheimer's disease, Multiple sclerosis functional composite, CEO, MS, Magnetic resonance imaging, Biomarker, EMB Consultancy, HIV disease progression rates, Technology, Gold, GMB (trade union), Neuroscience, Multiple sclerosis, Digital, Pharmaceutical industry, Medical imaging

MONTREAL, Oct. 5, 2021 /PRNewswire/ -- Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).

Key Points: 
  • MONTREAL, Oct. 5, 2021 /PRNewswire/ -- Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).
  • "The financing from Novartis will fund a carefully designed cross-sectional and longitudinal MS study that will last until 2027.
  • "This partnership is the result of an ongoing collaboration that was architected over the past two years.
  • "At Novartis, we are committed to innovation and becoming the leaders in the health tech space.